CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 408 enrolled
Drug / intervention
E-vapour product +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02029196
NCT02029196N/ACompleted
CompareCT.gov

A Randomised, Parallel Group, Multi-centre Study to Evaluate the Safety Profile of the ITG EVP G1 Product

Imperial Brands PLC·interventional·Posted Jan 7, 2014·Updated Mar 21, 2017

In Brief

A clinical study evaluating E-vapour product and Conventional cigarette for Healthy Volunteers. Completed, enrolled 408 participants across 2 sites.

Detailed Summary

Electronic Vapour Products (EVPs) is a relatively new class of consumer products that are otherwise known as electronic cigarettes or electronic nicotine delivery devices/systems. These may look like conventional cigarettes but do not contain tobacco. The 'vapour' produced by such devices typically consists of humectants (propylene glycol or glycerol), nicotine, water, and flavours. This trial is to evaluate the safety of an e-vapour product.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited Kingdom
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 7, 2014
Enrollment StartDec 1, 2013
Primary CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 12.5 years ago

Interventions

E-vapour productother

Smokers of conventional cigarettes who switch to use an e-vapour product.

Conventional cigaretteother

Smokers of conventional cigarettes who continue smoking conventional cigarettes.